Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acetylglutamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.42 |
| ▸ | FNTB | P49356 | 12/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 10/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aceglumate SCHEMBL28885877 | 1.00 | FNTA (0.42) | FNTAFNTBPGGT1BFOLH1NOD1 | |
| Aceglumate SCHEMBL21055962 | 1.00 | FNTA (0.42) | FNTAFNTBPGGT1BFOLH1NOD1 | |
| Aceglumate SCHEMBL28443403 | 1.00 | FNTA (0.42) | FNTAFNTBPGGT1BFOLH1NOD1 | |
| Arginine SCHEMBL4059260 | 0.91 | ALOX15 (0.45) | FNTAFNTBPGGT1BFOLH1NOD1 | |
| Arginine SCHEMBL458502 | 0.91 | ALOX15 (0.45) | FNTAFNTBPGGT1BFOLH1NOD1 | |
| Arginine SCHEMBL6668510 | 0.88 | FOLH1 (0.51) | FOLH1NOD1KMT2A | |
| Arginine SCHEMBL18660568 | 0.87 | ALOX15 (0.49) | FNTAFNTBPGGT1BNOD1ALOX15 | |
| Arginine SCHEMBL6517506 | 0.87 | ALOX15 (0.49) | FNTAFNTBPGGT1BNOD1ALOX15 | |
| Arginine SCHEMBL4052601 | 0.87 | ALOX15 (0.49) | FNTAFNTBPGGT1BNOD1ALOX15 | |
| SCHEMBL30463274 | 0.87 | FOLH1 (0.46) | FNTAFNTBPGGT1BFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271012-B1 | DEVICES FOR PROVIDING SKIN CARE USING PHOTOTHERAPY | INDERM (FR) | 2019-06-19 | — | — | EP | claimed |
| US-20180071547-A1 | Methods of Providing Skin Care Using Phototherapy | INDERM (FR) | 2018-03-15 | — | — | US | claimed |
| EP-3271012-A1 | METHODS OF PROVIDING SKIN CARE USING PHOTOTHERAPY | Inderm (FR) | 2018-01-24 | — | — | EP | claimed |
| WO-2016146778-A1 | METHODS OF PROVIDING SKIN CARE USING PHOTOTHERAPY | INDERM (FR) | 2016-09-22 | — | — | WO | claimed |
| US-20220409497-A1 | DELIVERY PARTICLE | PROCTER & GAMBLE (US) | 2022-12-29 | — | — | US | disclosed |
| EP-2785768-B2 | CONSUMER PRODUCT COMPOSITIONS COMPRISING ORGANOPOLYSILOXANE EMULSIONS | PROCTER & GAMBLE (US) | 2022-07-13 | — | — | EP | disclosed |
| US-10953237-B2 | Methods of providing skin care using phototherapy | INDERM (FR) | 2021-03-23 | — | — | US | disclosed |
| EP-3733827-A1 | DELIVERY PARTICLES | The Procter & Gamble Company (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-2877521-B1 | CONSUMER PRODUCT COMPOSITIONS COMPRISING ORGANOPOLYSILOXANE CONDITIONING POLYMERS | PROCTER & GAMBLE (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10639288-B2 | Anti-aging skin care compositions and regimens | THE PROCTER & GAMBLE COMPANY (US) | 2020-05-05 | — | — | US | disclosed |
| EP-2563508-B1 | DELIVERY PARTICLE | PROCTER & GAMBLE (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3271012-B1 | DEVICES FOR PROVIDING SKIN CARE USING PHOTOTHERAPY | INDERM (FR) | 2019-06-19 | — | — | EP | disclosed |
| US-20080038216-A1 | Personal care composition | PROCTER & GAMBLE COMPANY, THE | 2008-02-14 | — | — | US | disclosed |
| WO-2008018045-A2 | PERSONAL CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20080031833-A1 | Combined energy and topical composition application for regulating the condition of mammalian skin | PROCTER & GAMBLE COMPANY, THE | 2008-02-07 | — | — | US | disclosed |
| US-20070297996-A1 | Multi-phase composition comprising a sunscreen | THE PROCTER & GAMBLE COMPANY | 2007-12-27 | — | — | US | disclosed |
| US-20070297997-A1 | Personal care composition | THE PROCTER & GAMBLE COMPANY | 2007-12-27 | — | — | US | disclosed |
| WO-2007148292-A1 | MULTI-PHASE COMPOSITION COMPRISING A SUNSCREEN | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007148293-A2 | PERSONAL CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070264210-A1 | Method of enhancing penetration of water-soluble actives | THE PROCTER & GAMBLE COMPANY | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409497-A1 | DELIVERY PARTICLE | LIPA, CHMP4B, SLC46A1 | FNTA 1846/4885FNTB 2092/4885PGGT1B 2982/4885 |
| US-20070297997-A1 | Personal care composition | ERCC1, CUTA, ERCC5 | FNTA 3198/4885FNTB 3812/4885PGGT1B 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.